ACRS News and Press, Aclaris Therapeutics Inc. From 01/11/22

WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on...

WAYNE, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will particip...

WAYNE, Pa., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the publication of preclinical research of zunsemetinib in pancre...

Investigational New Drug Application for ATI-2138 Allowed WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today annou...

Aclaris Therapeutics (NASDAQ:ACRS): Q3 GAAP EPS of -$0.35 misses by $0.07. Revenue of $1.65M (+17.9% Y/Y) misses by $0.12M. Press Release Shares -2.11% PM For further details see: Aclaris Therapeutics EPS misses by $0.07, misses on revenue

Investigational New Drug Application for ATI-2138 for the Treatment of Psoriasis Submitted in October 2021 Planning to Initiate Phase 2b Trial of Zunsemetinib (ATI-450) in Moderate to Severe Rheumatoid Arthritis in the Fourth Quarter of 2021 WAYNE, Pa., Nov. 02, ...

After the recent FDA black box warning of JAKi, Arena Pharmaceuticals' share price has rallied recovering some of its 2021 losses. In this article, Etrasimod's ulcerative colitis phase 2 data will be analyzed and explain what our views for the S1P-R class moving forward. Arena Pha...

The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this event. For further details see: Aclaris Therapeutics (ACRS) Presents At 23rd Annual Global Investment Virtual Conference - Slideshow

WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the “Settlement Hearing”...

Public Offering with Net Proceeds of $134.9 Million in June Strengthens Balance Sheet and Extends Cash Runway Through the End of 2024 Positive Preliminary Topline Data for Phase 2a Trial of ATI-1777 in Moderate to Severe Atopic Dermatitis Announced in June Adva...